Vetigenics

Easter is full of fun, but it can also pose hidden dangers for our furry friends. 🐾 From toxic treats to festive flowers, a few simple precautions can help keep pets safe and healthy this holiday weekend. Swipe through for quick tips every pet parent should know! 💐🍫🐶🐱 #PetSafety #EasterPets #Vetigenics #PetHealth #EasterTips #DogSafety #CatSafety #PetWellness

🚀 Exciting news! Vetigenics has been named Startup of the Month in the 2024 Philadelphia Venture Report, which highlights regional growth in venture funding and features standout Penn spinouts. Co-founded by Dr. Nicola Mason (Penn Vet), Dr. Don Siegel (Penn Medicine), and Adriann Sax (President, CEO & Co-Founder), Vetigenics is proud to be at the forefront of developing antibody-based therapeutics for pets with cancer and chronic diseases. 🐶🐱 Thank you to PCI Ventures and our growing community of supporters helping us bring cutting-edge immunotherapies to veterinary medicine. 🔗 Read more: https://lnkd.in/eJz3kaaj #biotech #startupofthemonth #animalhealth #pethealth #vetmed #immunotherapy #PennSpinout #PhiladelphiaInnovation #Vetigenics #antibodies #mAbs #Pets #dogs

🚨 ONE SPOT LEFT! 🚨 A clinical trial evaluating an innovative treatment for dogs with Urothelial Carcinomahas just ONE final opening. 🐶 About the Trial: This study is investigating VGS-002, a fully canine anti-PD1 antibody designed to enhance anti-tumor immunity. Vetigenics is proud to provide this investigational therapy to support ongoing veterinary cancer research. 📍 Trial Locations: ✅ San Marcos, CA ✅ Boulder, CO ✅ Edmonds, WA 💡 Why Participate? - Access to a cutting-edge investigational therapy at no cost - Contribute to advancements in veterinary oncology - Potentially improve your dog’s quality of life This is a rare opportunity—help us find the final eligible dog! Tag a friend, share this post, or reach out to learn more. 🔗 https://lnkd.in/ghnjxAhA 🔗 https://lnkd.in/epURyPzM #VeterinaryMedicine #ClinicalTrial #CancerResearch #DogsWithCancer #Oncology #Vetigenics #Dogs #mAbs #Immunotherapy #UrothelialCarcinoma #BladderCancer #PetHealth #Biotech #Pets

Best part of my job? Getting to visit with #innovative startups in PA. Even better? When one of said startups is working to improve health outcomes for companion animals! Vetigenics, a Philadelphia startup spun out of University of Pennsylvania, is doing just that. Congratulations to Adriann Sax and team for the recent $6m seed round. My dog Harley and I look forward to seeing you grow in Philadelphia. #DCED #PAGetsItDone #innovation #dogmom #techtransfer #Blabs

We’re in the news! 📰 🐾 Innovation News Network spotlighted Vetigenics and our work developing next-generation antibody therapies for pets. With our CANIBODY™ platform, we’re creating treatments designed specifically for companion animals—bringing the power of biotechnology to veterinary medicine. Read more about how we’re advancing pet health: 🔗 https://lnkd.in/epbvWa4C #Vetigenics #PetHealth #VeterinaryMedicine #Biotech #mAbs #Antibody #PhageDisplay #Dogs #Animals #Pets #AnimalHealth #Veterinarian

Vetigenics is a clinical-stage animal health biotech company dedicated to advancing veterinary medicine with cutting-edge antibody therapies. The company specialises in developing targeted treatments for cancer and chronic diseases in companion animals, leveraging our proprietary phage display technology to create safer, more effective therapies tailored to the unique biology of our pets. At the core of the company is the CANIBODY™ platform, an entirely canine phage display library that accelerates the discovery and development of antibodies tailored for pets. Unlike treatments adapted from human or murine sources, our species-specific antibodies offer greater safety and efficacy, ensuring that pets receive the best possible care. Learn more about Vetigenics and its mission: https://bit.ly/4gTdPus #biotech #cancerresearch #animalhealth

Vetigenics Secures $6M to Advance Targeted Antibody Therapies for Pets 🐶 Philadelphia-based biotech startup Vetigenics has raised $6 million in seed funding to accelerate clinical trials for groundbreaking pet antibody treatments. 𝗪𝗵𝘆 𝗧𝗵𝗶𝘀 𝗠𝗮𝘁𝘁𝗲𝗿𝘀 🔬 CANIBODY™ technology: Develops targeted antibody therapies for cancer and chronic diseases in pets. ⚕️ Proven human treatments, now for pets: Adapting advanced human immunotherapy for veterinary use. 🚀 Upcoming clinical trials: Key therapies targeting oral melanoma & urothelial carcinoma in dogs. 𝗠𝗮𝗷𝗼𝗿 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀 𝗨𝗻𝗱𝗲𝗿𝘄𝗮𝘆 📌 VGS-001 (anti-cCTLA4) + palliative radiation for oral melanoma → Trial complete, results in 2025. 📌 VGS-002 (anti-cPD1) as monotherapy for urothelial carcinoma → Results expected later this year. 𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘅𝘁 𝗳𝗼𝗿 𝗩𝗲𝘁𝗶𝗴𝗲𝗻𝗶𝗰𝘀? ✅ Pivotal trials & preclinical candidate acceleration ✅ Scaling operations & manufacturing ✅ Expanding strategic partnerships in animal health & oncology With a strong leadership team and cutting-edge technology, Vetigenics is set to redefine cancer treatment for pets. 🐕💉 ----- 🚀 Follow The Big Deal © for more amazing startup stories! : https://shorturl.at/k2VJH

🚀 Exciting news from Vetigenics! 🚀 With major progress in our clinical trials and new therapies in the pipeline, we’re taking pet antibody therapeutics to the next level. And with fresh support from our investors, we’re accelerating even faster. See what’s ahead: https://lnkd.in/exkzA7VP #AnimalHealth #Biotech #Vetigenics #PetTherapeutics #AntibodyTherapy #Pets #Dogs #Antibodies #mAbs #ClinicalTrial #Immunotherapy

Vetigenics was proud to sponsor the K9 Talent Show at Marty’s Place Senior Dog Sanctuary’s Howl-O-Ween Family Fest this past weekend! It was a wonderful event for an incredible cause, and we were thrilled to see such a great turnout. A special shout-out to our very own Adriann Sax, who had the tough job of judging the impressive K9 talent. Thanks to everyone who made this event such a success! #supportingseniordogs #howloween #vetigenics #martysplaceseniordogsanctuary #dogs #k9talent

🎙️ Thrilled to announce that Dr. Nicola Mason, one of our founders, is featured in Episode 19 of the Veterinary Cancer Pioneers Podcast! In this episode, Dr. Mason shares her insights on the advancements in veterinary oncology and immunotherapy from her work at the University of Pennsylvania. She discusses leading the first canine cancer immunotherapy consortium supported by the Cancer Moonshot Initiative and the exciting potential of new therapies for both dogs and humans. Her pioneering research and commitment to improving cancer treatment for pets resonate with our mission at Vetigenics. We proudly support her groundbreaking work, which not only enhances veterinary medicine but also contributes to significant advancements in cancer research. Tune in to discover how Dr. Mason is shaping the future of veterinary science! https://lnkd.in/eEFUxD6N